Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
We examined the effect of intravenously infused glucagon-like peptide 1 (GLP-1) on subjective appetite sensations after an energy-fixed breakfast, and on spontaneous energy intake at an ad libitum lunch. 20 young, healthy, normal-weight men participated in a placebo-controlled, randomized, blinded, crossover study. Infusion (GLP-1, 50 pmol/ kg.h or saline) was started simultaneously with initiation of the test meals. Visual analogue scales were used to assess appetite sensations throughout the experiment and the palatability of the test meals. Blood was sampled throughout the day for analysis of plasma hormone and substrate levels. After the energy-fixed breakfast, GLP-1 infusion enhanced satiety and fullness compared with placebo (treatment effect: P < 0.03). Furthermore, spontaneous energy intake at the ad libitum lunch was reduced by 12% by GLP-1 infusion compared with saline (P = 0.002). Plasma GLP-1, insulin, glucagon, and blood glucose profiles were affected significantly by the treatment (P < 0.002). In conclusion, the results show that GLP-1 enhanced satiety and reduced energy intake and thus may play a physiological regulatory role in controlling appetite and energy intake in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RA increase satiety, reduce food intake and delay gastric emptying whilst they also stimulate insulin release and inhibit glucagon secretion in a glucose-dependent manner (Fig. 1) [17, 18].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Short-term studies have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RA) induce weight loss by promoting satiety and reducing hunger16–19.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, non-clinical and clinical studies have demonstrated increased satiety, reduced food intake and subsequent reductions in body weight following administration of GLP-1,7, 8”
From Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults (2014) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [3]
In the citing paper
“GLP-1 receptor agonists (GLP-1RA) have been shown to promote weight loss and decrease liver fat [28,29] (Figure 1).”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [29]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1975) · Journal of AOAC INTERNATIONAL · doi:10.1093/jaoac/58.5.1085 · Cited by 19,795
(1974) · Elsevier eBooks · doi:10.1016/b978-0-12-091304-6.x5001-0 · Cited by 6,755
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Cited by
Items 601–700 of 1,003
Daousi, C., Pinkney, J. H., Cleator, J., Wilding, J. P. H., & Ranganath, L. R. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.03.004 · Cited by 38
Search for α-helical propensity in the receptor-bound conformation of glucagon-like peptide-1
Murage, E. N., Schroeder, J. C., Beinborn, M., & Ahn, J. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.006 · Cited by 146
Yang, Z., Yu, M., Mei, M., Chen, C., Lv, Y., Xiang, L., & Li, R. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.10.003 · Cited by 37
Aukan, M. I., Coutinho, S., Pedersen, S. A., Simpson, M. R., & Martins, C. (2023) · Obesity Reviews · doi:10.1111/obr.13531 · Cited by 39
“In laboratorial settings, infusion of GI hormones has been shown to affect eating behavior in both individuals with normal-weight and obesity.(12,86,138,139,151) However, the association between plasma concentration of GI hormones and appetite ratings is highly complex and”
BackgroundFood intake in lean and obese mice after peripheral administration of glucagon-like peptide 2
Baldassano, S., Bellanca, A., Serio, R., & Mulè, F. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0092 · Cited by 38
Maciel, M. G., Beserra, B. T. S., Oliveira, F. C. B., Ribeiro, C. M., Coêlho, M. S., Neves, F. D. A. R., & Amato, A. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.034 · Cited by 39
Overgaard, R. V., Lindberg, S. Ø., & Thielke, D. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13479 · Cited by 34
“ing and enhancing satiety, which in turn leads to reduced energy intake.(7) Semaglutide (Novo Nordisk, Denmark) is a once-weekly human”
BackgroundHansen, T. T., Andersen, S. V., Astrup, A., Blundell, J., & Sjödin, A. (2019) · Obesity Reviews · doi:10.1111/obr.12854 · Cited by 37
Self-citationHoerger, T. J., & Ahmann, A. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s1-b.1 · Cited by 42
“Because GLP-1 is itself rapidly degraded by DPP-IV, there are 2 strategies for receptor activation: enzyme inhibitors and incretin mimetics that stimulate the GLP-1 receptor.(50) DPP-IV inhibitors—By inhibiting GLP-1 breakdown, DPP-IV inhibitors increase meal-stimulated active GLP-1 and GIP levels 2-fold to 3-fold.”
BackgroundNew technologies and therapies in the management of diabetes.
Triplitt, C. L. (2007) · PubMed · Cited by 44
Gut: A key player in the pathogenesis of type 2 diabetes?
Muscogiuri, G., Balercia, G., Barrea, L., Cignarelli, A., Giorgino, F., Holst, J. J., Laudisio, D., Orio, F., Tirabassi, G., & Colao, A. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1252712 · Cited by 37
“In addition, GLP-1 reduces food intake, and elicits satiety and fullness in healthy subjects and patients with T2D (Flint et al., 1998; Gutzwiller et al., 1999; Meier et al., 2002).”
BackgroundSelf-citationSimonsen, L., Lau, J., Kruse, T., Guo, T., McGuire, J., Jeppesen, J. F., Niss, K., Sauerberg, P., Raun, K., & Dornonville de la Cour, C. (2022) · PLOS ONE · doi:10.1371/journal.pone.0264974 · Cited by 36
“GLP-1, produced and secreted by intestinal L-cells in response to nutrients, improves glucose homeostasis [7], while simultaneously lowering body weight by reducing energy intake [8].”
BackgroundKapitza, C., Zdravkovic, M., Hindsberger, C., & Flint, A. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0044-y · Cited by 36
Self-citationIwao, T., Sakai, K., & Sata, M. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.07.001 · Cited by 36
Knudsen, L. B., Secher, A., Hecksher‐Sørensen, J., & Pyke, C. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12463 · Cited by 36
GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products
Guglielmi, V., & Sbraccia, P. (2016) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-016-0352-y · Cited by 42
Wang, L., Cheng, K., Li, Y., Niu, C., Cheng, J., & Niu, H. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.087 · Cited by 36
“In clinics, GLP-1 promotes satiety and suppresses energy intake in humans [38] and thereby GLP-1 analogues have been used to treat T1DM [39].”
MethodOral lactate slows gastric emptying and suppresses appetite in young males
Pedersen, M. G. B., Søndergaard, E., Nielsen, C. B., Johannsen, M., Gormsen, L. C., Møller, N., Jessen, N., & Rittig, N. F. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.12.032 · Cited by 44
Feinle, C., O'Donovan, D., & Horowitz, M. (2002) · Nutrition Reviews · doi:10.1301/002966402320243241 · Cited by 36
On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus.
Vilsbøll, T. (2004) · PubMed · Cited by 44
The gut and food intake: an update for surgeons
Näslund, E. B., Hellström, P. M., & Kral, J. G. (2001) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(01)80095-0 · Cited by 42
The effects of GLP-1 infusion in the hepatic portal region on food intake
Kim, D.-H., D'Alessio, D. A., Woods, S. C., & Seeley, R. J. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.03.002 · Cited by 37
Obesity: a 100 year perspective
Bray, G. A. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01530-6 · Cited by 44
“The importance of these peripheral factors has been strongly reinforced by showing that glucagon-like peptide-1 from the GI tract can reduce food intake [53] and that derivatives of this molecule can produce effective clinical agents for treating obesity.”
Astrup, A. V. (2024) · European Journal of Clinical Nutrition · doi:10.1038/s41430-024-01460-6 · Cited by 42
“The pivotal fi ndings of the study in which we infused GLP-1 in human subjects showed that it enhanced satiety reduced hunger during a fi xed breakfast meal and reduced spontaneous energy intake by 12% during an ad libitum lunch meal [6].”
BackgroundMethodInfluentialSelf-citationTreatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Hansen, K. B., Knop, F. K., Holst, J. J., & Vilsbøll, T. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02086.x · Cited by 35
Self-citationImplementation of GLP-1 Based Therapy of Type 2 Diabetes Mellitus Using DPP-IV Inhibitors
Holst, J. J. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-47920-6_33 · Cited by 39
Self-citationHarnessing the Therapeutic Potential of Glucagon-Like Peptide-1: A Critical Review
Baggio, L. L., & Drucker, D. J. (2002) · Treatments in Endocrinology · doi:10.2165/00024677-200201020-00005 · Cited by 36
“[44-52] The precise mechanisms underlying the satiety effect in humans, and the contribution of peripheral versus central mechanisms including possible activation of central aversive signaling, remains unclear.”
BackgroundIncretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.014 · Cited by 37
Cracking the combination: Gut hormones for the treatment of obesity and diabetes
Alexiadou, K., Anyiam, O., & Tan, T. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12664 · Cited by 34
Advances in GLP-1 treatment: focus on oral semaglutide
Eliaschewitz, F. G., & Canani, L. H. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00713-9 · Cited by 34
“Peripherally, GLP-1 reduces energy intake and affects all components of appetite regulation: increased satiety and fullness and decreased hunger and prospective food consumption [26, 27].”
BackgroundBremmer, M. P., & Hendershot, C. S. (2023) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.23-00318 · Cited by 31
Gaddy, D. F., Riedel, M. J., Pejawar‐Gaddy, S., Kieffer, T. J., & Robbins, P. D. (2010) · Diabetes · doi:10.2337/db09-1886 · Cited by 41
“GLP-1 then acts locally in the gut to inhibit gastric emptying and gastric acid secretion, leading to decreased food intake and reduced body weight (18,20,28,29).”
BackgroundKatsurada, K., Nandi, S. S., Sharma, N. M., Zheng, H., Liu, X., & Patel, K. P. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00028.2019 · Cited by 37
Shao, Y., Yuan, G., Zhang, J., & Guo, X. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s79175 · Cited by 33
Nutraceutical approaches to metabolic syndrome
Sirtori, C. R., Pavanello, C., Calabresi, L., & Ruscica, M. (2017) · Annals of Medicine · doi:10.1080/07853890.2017.1366042 · Cited by 37
“mechanisms linking probiotics and body weight reduction there are the ability (i) of the microbioma to extract energy from the diet [99] and (ii) to increase the secretion of the gut hormone glucagon-like peptide (GLP-1) enhancing satiety and reducing energy intake [100].”
BackgroundNovel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
“Furthermore, they possess an inherent ability to reduce glucagon secretion (Kreymann et al., 1987), delay gastric emptying (Näslund et al., 1998a) and promote satiety (Flint et al., 1998).”
BackgroundGao, L., Zhao, F.-L., & Li, S. (2012) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462312000608 · Cited by 35
“glucose-dependent manner, inhibiting glucagon secretion, hepatic glucose output, decelerating gastric emptying and reducing appetite and food intake (8;10;20;27).”
BackgroundBitarafan, V., Fitzgerald, P. C. E., Little, T. J., Meyerhof, W., Jones, K. L., Wu, T., Horowitz, M., & Feinle‐Bisset, C. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00294.2019 · Cited by 34
“Glucagon-like peptide-1 (GLP-1) is of particular interest, as it slows gastric emptying, stimulates insulin in the presence of glucose, and reduces energy intake (12, 14, 22).”
BackgroundIdentifying stress-related eating in behavioural research: A review
Stammers, L., Wong, L., Brown, R., Price, S., Ekinci, E., & Sumithran, P. (2020) · Hormones and Behavior · doi:10.1016/j.yhbeh.2020.104752 · Cited by 31
Antidiabetic Effects of Pediococcus acidilactici pA1c on HFD-Induced Mice
Cabello-Olmo, M., Oneca, M., Pajares, M. J., Jiménez, M., Ayo, J., Encío, I., Barajas, M. A., & Araña, M. (2022) · Nutrients · doi:10.3390/nu14030692 · Cited by 34
“For example, it can reach the brain, affecting appetite and, consequently, food intake [83].”
BackgroundHage, M. P., Safadi, B. Y., Salti, I., & Nasrallah, M. (2012) · ISRN Endocrinology · doi:10.5402/2012/504756 · Cited by 36
“Furthermore, it inhibits glucagon secretion, delays gastric emptying and indirectly decreases food intake [44].”
BackgroundChan, S. W., Lin, G., Yew, D. T. W., Yeung, C. K., & Rudd, J. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.01.013 · Cited by 33
“GLP-1 also reduces food intake and enhances satiety in rats and humans, both lean and obese (Flint et al., 1998; Naslund et al., 1998; Turton et al., 1996).”
Usinger, L., Hansen, K. B., Kristiansen, V. B., Larsen, S., Holst, J. J., & Knop, F. K. (2011) · Obesity Surgery · doi:10.1007/s11695-011-0362-9 · Cited by 38
“It enhances satiety and reduces food intake probably due to a combination of activation of GLP-1 receptors in the central nervous system and inhibition of gastrointestinal motility—including gastric emptying [40].”
BackgroundSelf-citationImpact of Gastric Bypass Surgery on Gut Hormones and Glucose Homeostasis in Type 2 Diabetes
Näslund, E. B., & Kral, J. G. (2006) · Diabetes · doi:10.2337/db06-s012 · Cited by 36
“” Both GLP-1 and PYY release are augmented after GBP and have been shown independently to decrease food intake in humans (67,71).”
BackgroundTeeuwisse, W. M., Widya, R. L., Paulides, M., Lamb, H. J., Smit, J. W. A., Roos, A., van Buchem, M. A., Pijl, H., & van der Grond, J. (2012) · Diabetes · doi:10.2337/db11-1835 · Cited by 35
Gut Hormones Ghrelin, PYY, and GLP-1 in the Regulation of Energy, Balance, and Metabolism
Pérez–Tilve, D., Nogueiras, R., Mallo, F., Benoit, S. C., & Tschoep, M. H. (2006) · Endocrine · doi:10.1385/endo:29:1:61 · Cited by 42
Schou, J. H., Pilgaard, K. A., Vilsbøll, T., Jensen, C. B., Deacon, C. F., Holst, J. J., Vølund, A., Madsbad, S., & Vaag, A. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0382 · Cited by 33
Self-citationGogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2356254 · Cited by 32
“Moreover, GLP-1 reduces appetite and food intake [25].”
BackgroundGu, W., Lloyd, D. J., Chinookswong, N., Komorowski, R., Sivits, G. N., Graham, M., Winters, K. A., Yan, H., Boros, L. G., Lindberg, R. A., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.179986 · Cited by 36
“GLP-1 also enhances satiety and decreases energy intake (Flint et al., 1998; Näslund et al., 1999).”
BackgroundLim, J. J., & Poppitt, S. D. (2019) · Nutrients · doi:10.3390/nu11071517 · Cited by 33
“[68] M 19 fixed meal (t = 0) t = 0–240, 270–300 GLP-1total 0.”
Chassé, É., Guay, F., Knudsen, K. E. B., Zijlstra, R. T., & Létourneau-Montminy, M.-P. (2021) · Animals · doi:10.3390/ani11092598 · Cited by 40
“The ileal brake is a signal inhibiting feed intake, and it is stimulated by the presence of nutrients in the ileum [56].”
BackgroundHao, T., Zhang, H., Li, S., & Tian, H. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.2910 · Cited by 36
Gut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity
Field, B. C. T., Wren, A., Cooke, D., & Bloom, S. R. (2008) · Drugs · doi:10.2165/00003495-200868020-00002 · Cited by 38
Additive Effects of Glucagon-Like Peptide 1 and Pioglitazone in Patients With Type 2 Diabetes
Zander, M., Christiansen, A. L., Madsbad, S., & Holst, J. J. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1910 · Cited by 32
Self-citationde la Peña, A., Cui, X., Geiser, J., & Loghin, C. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0531-7 · Cited by 31
Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Maio, G. D., Monda, M., & Marra, M. L. (2025) · Healthcare · doi:10.3390/healthcare13121437 · Cited by 37
Perugini, R. A., & Malkani, S. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283446c1f · Cited by 31
Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents
Blonde, L., & Montanya, E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01575.x · Cited by 34
“Native GLP-1 can slow accelerated emptying of the stomach, and slow acid secretion, contributing to its effectiveness at lowering postprandial hyperglycaemia [5,7].”
BackgroundTargeting the intestinal L-cell for obesity and type 2 diabetes treatment
Albrechtsen, N. J. W., Kuhre, R. E., Deacon, C. F., & Holst, J. J. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.862152 · Cited by 34
Self-citationMottalib, A., Yusof, B. N. M., Shehabeldin, M., POBER, D. M., Mitri, J., & Hamdy, O. (2016) · Nutrients · doi:10.3390/nu8070443 · Cited by 33
“It also slows gastric emptying and induces satiety [7,8].”
BackgroundClinical Pharmacokinetics and Pharmacodynamics of Albiglutide
Brønden, A., Knop, F. K., & Christensen, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0499-8 · Cited by 33
“Additionally, the combination of reduced enteric motility, which delays carbohydrate absorption [10], and the activation of GLP-1 receptors in the central nervous system, which promotes satiety and ultimately weight loss [8, 11], are also beneficial.”
BackgroundVenom peptides as pharmacological tools and therapeutics for diabetes
Robinson, S. D., & Safavi-Hemami, H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.001 · Cited by 33
“In addition to stimulation of insulin secretion, GLP-1 inhibits glucagon secretion, delays gastric emptying and suppresses appetite (Flint et al., 1998; Komatsu et al., 1989; Wettergren et al., 1993; Willms et al., 1996).”
BackgroundThe Anti-Inflammatory Effect of Novel Antidiabetic Agents
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Life · doi:10.3390/life12111829 · Cited by 35
Kumar, K. G., Poole, A. C., York, B., Vólaufová, J., Zuberi, A. R., & Richards, B. K. S. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00491.2006 · Cited by 32
“In both humans and animals, GLP-1 stimulates insulin secretion from pancreatic -cells in response to glucose ingestion and inhibits gastric acid secretion and gastric emptying (11, 15, 16).”
BackgroundSharma, R., Sun, H., Piotrowski, D. W., Ryder, T. F., Doran, S. D., Dai, H. I., & Prakash, C. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.047316 · Cited by 31
“The data from these studies suggest that PF-00734200 is eliminated by both metabolism and renal clearance.”
BackgroundMethodBush, M., Scott, R., Watanalumlerd, P., Zhi, H., & Lewis, E. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.11.2613 · Cited by 30
Vilsbøll, T., & Garber, A. J. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01579.x · Cited by 30
“Liraglutide-induced weight loss in human beings may be attributed to feelings of satiety and fullness [87] that results in a decreased energy intake [88].”
BackgroundCalabria, A. C., Charles, L., Givler, S., & León, D. D. D. (2015) · Hormone Research in Paediatrics · doi:10.1159/000442155 · Cited by 32
Glucagon-like peptide 1 and the brain: Central actions–central sources?
Trapp, S., & Hisadome, K. (2010) · Autonomic Neuroscience · doi:10.1016/j.autneu.2010.09.008 · Cited by 32
Calissendorff, J., Gustafsson, T. P., Holst, J. J., Brismar, K., & Röjdmark, S. (2012) · Endocrine Research · doi:10.3109/07435800.2012.662662 · Cited by 32
“It has been shown that GLP-1 promotes satiety and suppresses energy intake in humans (27).”
BackgroundSelf-citationVora, J. P., Bain, S. C., Damcı, T., Dzida, G. J., Hollander, P. A., Meneghini, L., & Ross, S. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.08.002 · Cited by 34
GLP-1: Broadening the incretin concept to involve gut motility
Hellström, P. M. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.04.004 · Cited by 30
Andrews, C. N., Bharucha, A. E., Camilleri, M., Low, P. A., Seide, B. M., Burton, D. D., Baxter, K. L., & Zinsmeister, A. R. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00403.2006 · Cited by 35
“Although GLP-1 increases satiety via central mechanisms in rats (47), peripherally administered GLP-1 also increased satiety in humans (12, 16).”
BackgroundEmerging role of GLP-1 receptor agonists in the treatment of obesity
Neff, L. M. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s6816 · Cited by 36
“In humans, peripheral administration of GLP-1 has been shown to increase satiety and reduce energy intake.(28,29) Studies suggest that chronic administration of GLP-1 can reduce body weight in both rats(30) and humans.”
The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs
Rodbard, H. W. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0103 · Cited by 30
“…and safety of the implantable osmotic pump for administration of exenatide or other relatively rapidly cleared analogs, the potential clinical utility of an oral preparation of semaglutide, 67 and the effectiveness of GLP-1 RAs for management of obesity 57,68 and of nonalcoholic hepatosteatosis.”
No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century
Hope, D. C. D., Tan, T., & Bloom, S. R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00442 · Cited by 35
“Following on from this, continuous subcutaneous infusion of GLP-17−36NH2 in both lean and obese humans was shown to cause an increase in satiety and reduction of food intake (22, 23).”
BackgroundInvestigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide
González, C. D., Beruto, V., Keller, G. A., Santoro, S., & Girolamo, G. D. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.887 · Cited by 32
“Regarding appetite, a reduction in food intake as well as an increase in satiety has been attributed to GLP-1 [22].”
BackgroundPharmacotherapy of Diabetes: New Developments
Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 37
Management of type 2 diabetes: the role of incretin mimetics
Stonehouse, A. H., Holcombe, J. H., & Kendall, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.15.2095 · Cited by 29
“These effects are probably mediated via circulating GLP-1 binding to receptors located in the hypothalamic nuclei and area postrema: areas of the CNS that lack the blood–brain barrier (Box 1) [29-31].”
BackgroundYang, G.-R., Zhao, X.-L., Jin, F., Shi, L.-H., & Yang, J.-K. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.386 · Cited by 29
“Patients were excluded if they (1) had previously been treated with GLP-1 agonist, DPP-4 inhibitor; (2) had a history of severe hypoglycemia; (3) had a history of diabetic ketoacidosis or hyperglycemia nonketotic hyperosmolar coma; (4) had impaired renal function (serum creatinine>97mmol/L in women,>106mmol/L in men);…”
BackgroundEffects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Di Folco, U., Vallecorsa, N., Nardone, M. R., Pantano, A. L., & Tubili, C. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01936-6 · Cited by 29
“GLP-1 receptors are also present in the gastrointestinal tract, in the cardiovascular system, and in the central nervous system, in particular in the nucleus of the solitary tract; these mediate a slowdown in gastric emptying, with an increase in the sense of satiety reduced hunger and lower energy intake [4, 5].”
BackgroundKorsatko, S., Jensen, L., Brunner, M., Sach‐Friedl, S., Tarp, M. D., Holst, A. G., Heller, S. R., & Pieber, T. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13422 · Cited by 29
Elahi, D., Angeli, F. S., Vakilipour, A., Carlson, O. D., Tomás, E., Egan, J. M., Habener, J. F., & Shannon, R. P. (2014) · Peptides · doi:10.1016/j.peptides.2014.06.004 · Cited by 29
Romantsova, T. I. (2018) · Obesity and metabolism · doi:10.14341/omet201813-11 · Cited by 30
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
Campbell, R. K., & Neumiller, J. J. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s7314 · Cited by 30
“glucagon secretion,(25,26) slowing of gastric emptying,(27,28) and increased satiety and decreased food intake.(29) While GLP-1 has demonstrated clinical utility in the management of patients with T2DM, endogenous GLP-1 is rapidly degraded by the enzyme DPP-4, resulting in a GLP-1 half-life of approximately 1–2 minute…”
Freemantle, N., Mamdani, M., Vilsbøll, T., Kongsø, J. H., Kvist, K., & Bain, S. C. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0142-y · Cited by 30
“GLP-1 itself increases satiety [9]; the GLP-1RA liraglutide has been shown to exert the same effect [10], and to be associated with weight loss [8].”
The post-prandial state and cardiovascular disease: relevance to diabetes mellitus
Ceriello, A. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(200003/04)16:2<125::aid-dmrr90>3.0.co;2-4 · Cited by 264
Campbell, R. K., & White, J. R. (2008) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721708317870 · Cited by 34
The Role of Gut Hormones in Diet-Induced Weight Change: A Systematic Review
Zhao, X., Han, Q., Gang, X., Lv, Y., Liu, Y., Sun, C., & Wang, G. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-115646 · Cited by 29
“Intravenous infusion of GLP-1 can induce significant decreased food intake and increased satiety [55].”
BackgroundGut peptides in the treatment of diabetes mellitus
Vahl, T. P., & D’Alessio, D. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.3.177 · Cited by 31
Riediger, T., Eisele, N., Scheel, C., & Lutz, T. A. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00438.2009 · Cited by 31
Mechanisms behind GLP-1 induced weight loss
Larsen, P. J. (2008) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/1474651408100525 · Cited by 28
“In humans, intravenous infusion of GLP-1 was demonstrated to decrease caloric intake and trigger premature satiety and sense of fullness.(11) A few years prior to these clinical pharmacological experiments, studies in rodents suggested that the brain is equipped with GLP-1-sensitive sites eliciting negative energy bal…”
BackgroundIkushima, I., Jensen, L., Flint, A., Nishida, T., Zacho, J., & Irie, S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0677-1 · Cited by 28
“GLP-1 also has effects on appetite and energy intake [13, 14] and is, therefore, an attractive pharmacologic option for the treatment of T2D [15–17].”
BackgroundSelf-citationCircadian rhythms in colonic function
Hibberd, T. J., Ramsay, S. D., Spencer-Merris, P., Dinning, P. G., Zagorodnyuk, V. P., & Spencer, N. J. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1239278 · Cited by 31
Gallas, S., Sinno, M. H., Boukhettala, N., Coëffier, M., Dourmap, N., Gourcerol, G., Ducrotte, P. R., Déchelotte, P., Leroi, A., & Fetissov, S. O. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07474.x · Cited by 31
“Among these is ghrelin, an orexigenic hormone produced mainly in the stomach (Kojima et al., 1999), and several intestinal satiety hormones such as peptide YY (PYY) (Batterham et al., 2002) and glucagon-like peptide 1 (GLP1) (Flint et al., 1998).”
BackgroundInfluentialIncretin therapy for diabetes mellitus type 2
Holst, J. J. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000516 · Cited by 32
“In addition to the effects on the islets, GLP-1RAs inhibit appetite and food intake [41] leading to weight losses.”
BackgroundSelf-citationDifferences in gastrointestinal hormones and appetite ratings among obesity classes
Aukan, M. I., Nymo, S., Ollestad, K. H., Boyesen, G. A., DeBenedictis, J. N., Rehfeld, J. F., Coutinho, S. R., & Martins, C. (2022) · Appetite · doi:10.1016/j.appet.2022.105940 · Cited by 31
Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
Dutta, P., Kumar, Y., Babu, A. T., Ravindran, S. G., Salam, A., Rai, B., Baskar, A., Dhawan, A., & Jomy, M. (2023) · Cureus · doi:10.7759/cureus.38379 · Cited by 46
“Moreover, GLP-1 agonists also have a satiety effect [19].”
Background
Metadata
- Authors
- Flint, A., Raben, A., Astrup, A., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-01
- Volume
- 101
- Issue
- 3
- Pages
- 515-520
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508592
- OpenAlex
- W1975756049
- Cited by
- 1,402
- References
- 40
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 62 · 2023: 33 · 2022: 55 · 2021: 53 · 2020: 49 · 2019: 44 · 2018: 52 · 2017: 49 · 2016: 54 · 2015: 59 · 2014: 64 · 2013: 74 · 2012: 72
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, satiety, appetite, energy intake, insulin, glucagon, blood glucose, appetite regulation, intravenous infusion
- MeSH terms
- Adult, Appetite, Appetite Depressants, Appetite Regulation, Blood Glucose, Energy Intake, Glucagon, Humans, Insulin, Male, Pain Measurement, Peptide Fragments, Protein Precursors, Satiation, Cross-Over Studies, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.